Article

Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis.

Repatriation General Hospital, Daws Rd, Daw Park 5041 South Australia.
Annals of the Rheumatic Diseases (impact factor: 8.73). 03/2006; 65(2):149-56. DOI:10.1136/ard.2005.037929 pp.149-56
Source: PubMed

ABSTRACT Modulation of Jak-STAT signalling may provide an effective therapeutic strategy in inflammatory arthritis.
To document Jak-STAT expression in a cohort of patients with active rheumatoid arthritis (RA), spondyloarthritis (SpA), and osteoarthritis (OA) and compare these subsets with normal synovial tissue.
Synovial tissue biopsy specimens from patients with RA, OA, and SpA and histologically normal tissue (n = 10 in each arthritis group) were examined for the presence of Jak3, STAT1, STAT4, and STAT6 expression using immunohistochemistry. Phenotyping was performed using immunohistochemistry and immunofluorescence. Clinical and serological characteristics of patients with RA expressing Jak3-STAT4 were assessed.
STAT1, STAT4, and Jak3 protein expression was generally increased in inflammatory arthritis. In contrast, STAT6 expression was relatively heterogeneous. A subpopulation of CD1a positive dendritic cells unique to seropositive patients with RA was detected. These cells showed intense protein expression for Jak3, STAT4, and STAT6.
CD1a positive dendritic cells intensely express Jak3, STAT4, and STAT6 in seropositive RA tissue and may be an alternative marker for dendritic cells in their early stages of activation as well as providing a tool for identifying RA at the level of the synovium. Jak3 inhibition may be a potential therapeutic target to prevent dendritic cell maturation in RA. STAT1 expression is increased in inflammatory arthritis, suggesting that its pro-apoptotic and anti-inflammatory effects cannot effectively counteract inflammation. STAT6 expression is heterogeneous in synovium, suggesting a possible homoeostatic role in addition to any anti-inflammatory effects.

0 0
 · 
0 Bookmarks
 · 
19 Views
  • Article: A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients.
    J Gu, E Märker-Hermann, D Baeten, W C Tsai, D Gladman, M Xiong, H Deister, J G Kuipers, F Huang, Y W Song, W Maksymowych, J Kalsi, M Bannai, N Seta, M Rihl, L J Crofford, E Veys, F De Keyser, D T Y Yu
    [show abstract] [hide abstract]
    ABSTRACT: To identify genes which are more highly expressed in the peripheral blood mononuclear cells (PBMC) of patients with spondyloarthropathy (SpA), rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in comparison to normal subjects. A 588-gene microarray was used as a screening tool to select a panel of such genes from PBMC of these subjects and of normal subjects. Results were then validated by reverse transcription-polymerase chain reaction (RT-PCR). The following genes were more highly expressed in arthritis patients than in normal subjects: macrophage differentiation marker MNDA (myeloid nuclear differentiation antigen), MRP8 and MRP14 (migratory inhibitory factor-related proteins); signalling molecules JAK3 (janus kinase 3) and MAP kinase p38 (mitogen-activated protein kinase); receptors TNFR2/p75, C-C-chemokine receptor type 1 (CCR1), C-X-C-chemokine receptor type 4 (CXCR4) and integrin beta1; and the cytokines/chemokines interleukin (IL) 1beta and IL-8. Expression of CXCR4 was unexpectedly high among all arthritis subjects. Using RT-PCR, ELISA and immunohistology, expression of stromal cell-derived factor 1 (SDF-1) was demonstrated in arthritis joints. The CXCR4/SDF-1 is a potential pro-inflammatory axis for RA, PsA and SpA.
    Rheumatology 08/2002; 41(7):759-66. · 4.06 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

active rheumatoid arthritis
 
alternative marker
 
anti-inflammatory effects
 
arthritis group
 
CD1a positive dendritic cells intensely
 
CD1a positive dendritic cells unique
 
dendritic cell maturation
 
dendritic cells
 
document Jak-STAT expression
 
effective therapeutic strategy
 
intense protein expression
 
Jak3 inhibition
 
Jak3 protein expression
 
Jak3-STAT4
 
normal synovial tissue
 
possible homoeostatic role
 
potential therapeutic target
 
seropositive patients
 
seropositive RA tissue
 
Synovial tissue biopsy specimens
 

J G Walker